Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Google Secures Pentagon AI Deal for Classified Projects 
BOSTON, Feb. 03, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced that the Company is scheduled to participate in a fireside chat at the LEERINK Partners
5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:30 a.m. ET.
The link to the live audio webcast and replay of the presentation may be accessed on the EPIRUS' website at http://ir.epirusbiopharma.com/events.cfm. The webcast will be archived on the Company's website for a period of three months.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)ii. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS' website at www.epirusbiopharma.com.
Contact Information: For media inquiries: Mike Devine, FleishmanHillard +1-212-453-2324 [email protected] For investor inquiries: Marek Ciszewski, J.D. EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected]
